IT - EN
News & Announcements

News & AnnouncementsBusiness & financial news

2017, October 26 - 11:51 RECORDATI: EXCELLENT RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%)
2017, July 27 - 11:14 RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.
2017, July 19 RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA
2017, July 7 Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
2017, July 3 - 08:01 RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED
2017, June 16 RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS
2017, May 22 - 08:01 RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE
2017, May 19 European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia
2017, May 4 - 12:49 RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%
2017, April 19 Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.
2017, April 13 Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®
2017, April 11 - 14:11 RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015)
2017, March 1 - 12:38 RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%)
2017, February 27 RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE
2017, February 9 - 12:03 RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED
2017, February 1 - 08:35 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN
2017, January 27 RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®
= price sensitive (as from 2015)